Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Impact of c242T Polymorphism of p22phox in Diabetic type1 Nephropathy (NEPHRODIANOX)

This study has been completed.
Information provided by (Responsible Party):
University Hospital, Grenoble Identifier:
First received: June 10, 2011
Last updated: November 14, 2013
Last verified: November 2013

The physiopathology of diabetic nephropathy (DN) is unclear. To investigate risk factor, the investigators choose to look about some oxidative stress genes. Today a one-gene explanation is not really possible. So the theory of some genetic predisposition to DN is more likely.

The aim of the study is to look about the association of the C282T polymorphism of P22phox, a sub unit of the nicotinamide adenine dinucleotide phosphate-oxidase (NADPH oxidase) in the occurrence of DN. To follow the oxidative stress pathway of the DN, the investigators also investigate three other polymorphisms: -429 T/C, -374 T/A polymorphism of advanced glycation end-products receptor (AGER) and the p.Arg261Gln polymorphism of the 12 lipoxygenase (ALOX 12). Discordant data suggest a link between the first 2 polymorphisms and DN. The last polymorphism is correlated to albuminuria in diabetic patients.

Type 1 Diabetes Mellitus
Diabetic Nephropathy

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Impact of c242T Polymorphism of p22phox in the Development of Diabetic Nephropathy,in Caucasian Diabetic Type 1 Patient.

Resource links provided by NLM:

Further study details as provided by University Hospital, Grenoble:

Primary Outcome Measures:
  • comparison of prevalence of homozygous polymorphism between the DN-group and the non-DN group [ Time Frame: on day 1 ]

Secondary Outcome Measures:
  • comparison of polymorphism of p22phox between the ND group and the sub-group of non-ND patients with diabetic retinopathy only [ Time Frame: day 1 ]
  • comparison of polymorphism prevalence between the 3 groups [ Time Frame: day 1 ]
  • delay between diabetes diagnosis and ND onset by genetic polymorphism [ Time Frame: 20 years ]
    Kaplan Meier method

Other Outcome Measures:
  • albuminuria [ Time Frame: day 1 ]

  • HbA1c [ Time Frame: day 1 ]
    HbA1c in %

Biospecimen Retention:   Samples With DNA
We will include 60 patients to reach the required number. We take 2 blood samples: one for genetic analysis and one to determine HBA1c and plasma creatinine. We also take one urinary sample to determine the urinary albumine / creatinine ratio

Enrollment: 162
Study Start Date: January 2011
Study Completion Date: March 2013
Primary Completion Date: March 2013 (Final data collection date for primary outcome measure)
diabetic nephropathy group
patient with diabetic nephropathy, defined as Albuminuria > 30 mg/day or urinary Albumine/ creatinine ratio > 3 mg/mmol ; or GFR estimated by MDRD less than 60 ml/min.1,73m². With no other etiology of diabetic nephropathy.
diabetic retinopathy group
patient with diabetic retinopathy defined as showing at least one micro aneurysm on retinography. Without nephropathy defined as above
no complication group
patient without diabetic nephropathy or retinopathy

Detailed Description:
To avoid confounding factors, we choose type 1 diabetic patients. We plan, with the data of literature a number need to be significative with a power of 80% and an Alpha risk at 5%, the inclusion of 160 patients for our primary analyze of p 22 phox. Those patients are included consequentially from the diabetic consultation of the university hospital of Grenoble, if they have a history of more than 20 years of diabetes. Those patients have been separated according to the existence of DN, and their polymorphism. Then we estimate with the Fisher test the prevalence of DN in risky patient, and the prevalence of the risky phenotype in the nephropathic patients. Then we investigate with the same statistical test the -429 T/C,he -374 T/A AGER and p.Arg261Gln 12 ALOX polymorphisms.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
caucasian diabetic type 1 patients with more than 20 years of diabetes duration

Inclusion Criteria:

  • caucasian
  • diabetic type 1
  • older than 18 years old
  • written consent

Exclusion Criteria:

  • other etiology of diabetic nephropathy
  • pregnancy
  • other type of diabetes
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01371955

University Hospital of Grenoble
Grenoble, France, 38043
Sponsors and Collaborators
University Hospital, Grenoble
Principal Investigator: BENHAMOU pierre yves, MD PhD service de diabétologie
  More Information

Responsible Party: University Hospital, Grenoble Identifier: NCT01371955     History of Changes
Other Study ID Numbers: 1020
2010-A01074-35 ( Registry Identifier: ID RCB )
Study First Received: June 10, 2011
Last Updated: November 14, 2013

Keywords provided by University Hospital, Grenoble:
diabetic nephropathy
Type 1 Diabetes Mellitus with Diabetic Dermatitis
more than twenty years of diabetes duration
older than 18 years
no nephropathy other than diabetic nephropathy

Additional relevant MeSH terms:
Diabetes Mellitus
Diabetes Mellitus, Type 1
Kidney Diseases
Diabetic Nephropathies
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Autoimmune Diseases
Immune System Diseases
Urologic Diseases
Diabetes Complications processed this record on April 28, 2017